Pharming Group
Pharming Group NV is a Dutch biopharmaceutical enterprise developing and commercializing protein replacement therapies and precision medicines for rare diseases. The company commercializes Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema, alongside Joenja for APDS immunodeficiency. Revenue is primarily generated through commercial sales of prescription orphan drugs to specialty distributors and healthcare providers. Core end markets encompass rare disease immunology centers, HAE treatment specialists, and clinical prescription patients across the United States and Europe. Pharming Group holds an established position in the global biopharmaceutical sector for recombinant C1 esterase inhibitor therapies in hereditary angioedema. The company is headquartered in Leiden, Netherlands, and its shares trade on Euronext Amsterdam and the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Pharming Group.
- Legal name
- Pharming Group NV
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 5
Funds holding Pharming Group
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.12 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- Nordea Internationale aktier — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)